Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms (MPNs).
According to Mesa, teamwork plays a key role in diversifying clinical trials.
The combined efforts of FDA stakeholders, pharmaceutical representatives, medical community members, academic centers, third-party payers, and patient advocacy groups are needed to continue the national conversation regarding the importance of diversity in clinical trials, Mesa explains.
Although significant work is needed, developing racially inclusive clinical trials could result in more broadly applicable data, concludes Mesa.